Northwest Biotherapeutics
Biotechnology, 9600 Medical CTR Dr, Bethesda, Maryland, 20850, United States, 11-50 Employees
Who is NORTHWEST BIOTHERAPEUTICS
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune...
Read More
-
Headquarters: 9600 Medical CTR Dr, Bethesda, Maryland, 20850, United States
-
Date Founded: 1998
-
Employees: 11-50
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
-
CEO:
Linda Powers
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from NORTHWEST BIOTHERAPEUTICS
Northwest Biotherapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Northwest Biotherapeutics
Answer: Northwest Biotherapeutics's headquarters are located at 9600 Medical CTR Dr, Bethesda, Maryland, 20850, United States
Answer: Northwest Biotherapeutics's official website is https://nwbio.com
Answer: Northwest Biotherapeutics's revenue is $100 Million to $250 Million
Answer: Northwest Biotherapeutics's SIC: 2834
Answer: Northwest Biotherapeutics's NAICS: 561110
Answer: Northwest Biotherapeutics has 11-50 employees
Answer: Northwest Biotherapeutics is in Biotechnology
Answer: Northwest Biotherapeutics contact info: Phone number: Website: https://nwbio.com
Answer: Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Companys approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Companys cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Companys platform technology, DCVax, uses a patients own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or antigens, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Companys lead product candidate is DCVax-Brain which targets Glioblastoma Multiforme (GBM), the most lethal form of brain cancer. DCVax-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or BLA) with the FDA for DCVax-Brain. DCVax-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month